Johnson & Johnson Receives Vaccine-Manufacturing Deal From U.S.
August 05 2020 - 9:21AM
Dow Jones News
By Matt Grossman
Johnson & Johnson has agreed to manufacture and deliver 100
million doses of its under-development Covid-19 vaccine for the
U.S. government, pending approval of the vaccine by the Food and
Drug Administration.
The federal government's vaccine-development effort committed
more than $1 billion in the deal, Johnson & Johnson said. The
government will have the option of buying an additional 200 million
doses, according to the company.
Johnson & Johnson is developing the vaccine through its
Janssen Pharmaceutical Cos. arm. Last week, Johnson & Johnson
said that a pre-clinical study in primates showed that the vaccine
provided complete or near-complete protection to the animals' lungs
from the SARS-CoV-2 virus, which causes Covid-19.
A clinical Phase 1/2a study of the vaccine's potential in human
subjects began last month, Johnson & Johnson said. The company
is evaluating both one-dose and two-dose vaccination regimes, it
said.
Johnson & Johnson said it plans to supply more than 1
billion doses of the vaccine through 2021 if it is shown to be safe
and effective.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
August 05, 2020 09:06 ET (13:06 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Sep 2023 to Sep 2024